(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/167217 A l 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: (72) Inventors: XIAO, Lei; Room 201, Building 4, 998 Halei A61K 39/00 (2006.01) C07K 14/705 (2006.01) Road, Pudong New Area, Shanghai 201203 (CN). WU, Zhao; Room 201, Building 4, 998 Halei Road, Pudong (21) International Application Number: New Area, Shanghai 201203 (CN). PU, Chengfei; Room PCT/CN20 17/078740 201, Building 4, 998 Halei Road, Pudong New Area, (22) International Filing Date: Shanghai 201203 (CN). CAO, Zhiyuan; Room 201, 30 March 2017 (30.03.2017) Building 4, 998 Halei Road, Pudong New Area, Shanghai 201203 (CN). SUN, He; Room 201, Building 4, 998 Halei (25) Filing Language: English Road, Pudong New Area, Shanghai 201203 (CN). BI, (26) Publication Language: English Mao; Room 201, Building 4, 998 Halei Road, Pudong New Area, Shanghai 201203 (CN). (30) Priority Data: 62/3 17,261 1 April 2016 (01.04.2016) US (74) Agent: BEIJING JWT INTELLECTUAL PROPERTY CO., LTD.; Suite 801, Tower 2, SoBoss Center, No. 16, (71) Applicant: INNOVATIVE CELLULAR THERAPEUT¬ South Sanhuan West Road, Fengtai District, Beijing ICS CO., LTD. [CN/CN]; Room 201, Building 4, 998 100068 (CN). Halei Road, Pudong New Area, Shanghai 201203 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, [Continued on nextpage] (54) Title: USE OF CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS TO TREAT CANCER Antigen Gene Cancer Types PRL. Prolact receptor Breast cancer. G C 2 G an t cyclase Colorectal cancer 2 1 II CD207 CD207 Bladder Cancer )1 < TSHR Thyroid ¾ FIG. 1 (57) Abstract: Compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells are dis- © closed. An isolated nucleic acid sequence encoding CAR is also disclosed. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind Q to an antigen of a non-essential organ. w o 2017/167217 A i llll II II 11III I II I III III II I II III II I II TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, VN, ZA, ZM, ZW. LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, (84) Designated States (unless otherwise indicated, for every GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Published: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, — with international search report (Art. 21(3)) TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Use of Chimeric Antigen Receptor Modified Cells to Treat Cancer CROSS REFERENCE TO RELATED PATENT APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62317261, filed on April 1, 2016, entitled "Use of chimeric antigen receptor modified cells to treat cancer," which is hereby incorporated by reference in its entirety. TECHNICAL FIELD The present disclosure relates to modified cells and uses, in particularly to compositions and methods for treating cancer using chimeric antigen receptor (CAR) modified cells. BACKGROUND Cancer is known as malignant tumors involving abnormal cell growth with the potential to invade or spread to other parts of the body. In humans, there are more than one hundred kinds of cancer, for example, breast cancer occurred in epithelial tissue of breast. Since breast cancer cells lose characteristics of normal cells, the connection between breast cancer cells is loose. Once the cancer cells are exfoliated, these exfoliated cancer cells spread over bodies via the blood or lymph systems and therefore become life-threatening. Currently, breast cancer has become one of the common threats to women's physical and mental health. Immunotherapy (e.g., CAR T) has been proved to be effective for treating cancer. But There is a need to improve the immunotherapy to be more effective for certain cancer such as solid tumors. SUMMARY Embodiments of the present disclosure relate to compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding a CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ. For example, the antigen binding domain binds to an antigen that is expressed on the surface of a non-essential organ cell present in a microenvironment of a tumor. Some embodiments of the present disclosure relate to an isolated CAR including an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ. Some embodiments of the present disclosure relate to a pharmaceutical composition including human T cells. The human T cells may include a nucleic acid sequence encoding a CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ. Some embodiments of the present disclosure relate to a cell including a nucleic acid sequence encoding a CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain binds to an antigen of a non-essential organ. For example, the cell is selected from the group consisting of a T cell, a natural killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell. Some embodiments of the present disclosure relate to a vector comprising a nucleic acid sequence encoding a CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ. Some embodiments of the present disclosure relate to a method for stimulating a T cell- mediated immune response to a cell population in a non-essential organ of a subject. The method may include administering to a subject an effective amount of a cell genetically modified to express a CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain is selected to recognize the cell population of the non-essential organ specifically. Some embodiments of the present disclosure relate to a method of treating a subject with cancer. The method may include administering to the subject a cell genetically engineered to express a CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ. For example, the cell is selected from the group consisting of a T cell, a natural killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell In some embodiments, the antigen binding domain is an antibody, an antigen-binding fragment thereof, or a ligand thereof. For example, the antigen-binding fragment is a Fab or a scFv. In some embodiments, the antigen is expressed on a non-essential organ cell present in a microenvironment of a tumor. In some embodiments, the tumor is a breast cancer. In certain embodiments, the antigen is a mammary gland antigen. For example, the mammary gland antigen is prolactin receptor (PRLR) having SEQ ID NO: 29. In some embodiments, the antigen binding domain is prolactin receptor ligand having SEQ ID NO: 20 or 44. In some embodiments, the tumor is colorectal cancer. In certain embodiments, the antigen is a colon antigen. For example, the colon antigen is Guanylate cyclase 2C (GUCY2C) having SEQ ID NO: 33 In some embodiments, the tumor is gastric cancer. In certain embodiments, the antigen is a gastric gland antigen. For example, the gastric gland antigen is Mucin 17 (Mucl7) having SEQ ID NO: 31. In some embodiments, the tumor is a bladder cancer. In certain embodiments, the antigen is a bladder antigen. For example, the bladder antigen is CD207 having SEQ ID NO: 35. In some embodiments, the tumor is an ovary tumor. In certain embodiments, the antigen is an ovary antigen. For example, the ovary antigen is Frizzled family receptor 10 (FZD10) having SEQ ID NO: 25. In some embodiments, the tumor is a thyroid tumor. In certain embodiments, the antigen is a thyroid antigen. For example, the thyroid antigen is Thyroid stimulating hormone receptor (TSHR) having SEQ ID NO: 27.